Komori

Presentation Materials for the Fiscal Year Ended September 2026

Results presentationFull year, FY ending Sep 2026Published 2026-11-16 16:00

For the fiscal year ended September 2026, sales declined year on year, while the operating loss, ordinary loss and net loss widened. In drug discovery research, 5 new Hits were generated, and the company moved into a phase aimed at generating Leads and monetising licensing revenue from fiscal 2027 onward.

In short

  • Net sales were ¥518 million, down from ¥677 million in the prior fiscal year.
  • The operating loss was ¥1,119 million, widening by ¥345 million from the prior fiscal year.
  • The company generated 5 new Hits in fiscal 2026 and is targeting 3 Leads and 4 new Hits in fiscal 2027.

What they reported

this period against the same period a year earlier, and where they now expect the year to end

Sales

¥518.0m−23.5%vs a year earlier
FY FY25/9¥677.0mFY FY26/9¥518.0m
FY24/9FY25/9FY26/9 · this year0200400¥mQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4+6%+30%+27%this yearvs same quarter last yearlast year
Sales by quarter
Period¥m
FY24/9 Q490.0
FY25/9 Q1125.0
FY25/9 Q293.0
FY25/9 Q391.0
FY25/9 Q4368.0
FY26/9 Q1132.0
FY26/9 Q2121.0
FY26/9 Q3116.0
result 518.0
Full year: forecast against result, ¥m
Why

Net sales declined by ¥159 million from the prior fiscal year.

Operating profit

−¥1.1bnloss widenedvs a year earlier
FY FY25/9−¥0.8bnFY FY26/9−¥1.1bn
FY24/9FY25/9FY26/9 · this year-0-0-00¥bnQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4▼▲this yearvs same quarter last yearlast year
Operating profit by quarter
Period¥bn
FY24/9 Q4-0.2
FY25/9 Q1-0.2
FY25/9 Q2-0.2
FY25/9 Q3-0.3
FY25/9 Q4-0.0
FY26/9 Q1-0.3
FY26/9 Q2-0.3
FY26/9 Q3-0.2
result -1.1
Full year: forecast against result, ¥bn
Why

The operating loss widened by ¥345 million from the prior fiscal year.

Ordinary profit

−¥1.1bnloss widenedvs a year earlier
FY FY25/9−¥0.7bnFY FY26/9−¥1.1bn
FY24/9FY25/9FY26/9 · this year-00¥bnQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4▼▲this yearvs same quarter last yearlast year
Ordinary profit by quarter
Period¥bn
FY24/9 Q4-0.3
FY25/9 Q1-0.2
FY25/9 Q2-0.3
FY25/9 Q3-0.3
FY25/9 Q4-0.0
FY26/9 Q1-0.3
FY26/9 Q2-0.3
FY26/9 Q3-0.2
result -1.1
Full year: forecast against result, ¥bn
Why

The ordinary loss widened by ¥340 million from the prior fiscal year.

Net profit

−¥1.2bnloss widenedvs a year earlier
FY FY25/9−¥0.8bnFY FY26/9−¥1.2bn
FY24/9FY25/9FY26/9 · this year-0-00¥bnQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4▼▲this yearvs same quarter last yearlast year
Net profit by quarter
Period¥bn
FY24/9 Q4-0.5
FY25/9 Q1-0.2
FY25/9 Q2-0.3
FY25/9 Q3-0.3
FY25/9 Q4-0.0
FY26/9 Q1-0.3
FY26/9 Q2-0.3
FY26/9 Q3-0.2
result -1.2
Full year: forecast against result, ¥bn
Why

The net loss widened by ¥350 million from the prior fiscal year.

Their own numbers

figures this company chose to report, a year ago against now
Hit discovery programs initiated
12 transactions

The company initiated 12 Hit discovery programs, including those started in the second half of fiscal 2025.

Programs with evaluation results
7 transactions

As of the end of September 2026, evaluation results had been obtained for 7 programs.

Hit acquisition programs
5 transactions

Hits were obtained in 5 of the 7 programs for which evaluation results were obtained.

Hit acquisition rate among programs with completed evaluations
71 %

The Hit acquisition rate among programs for which evaluation results were obtained was approximately 71%.

Lead generation in fiscal 2027
3 transactionsFY27/9 plan

The company will invest in priority Leads in fiscal 2027 and is targeting the generation of 3 Leads.

New Hit generation in fiscal 2027
4 transactionsFY27/9 plan

The company is targeting the generation of 4 new Hits in fiscal 2027.

Objective response rate for E7386
36.7 %

The objective response rate was 36.7% among 30 enrolled patients with advanced endometrial cancer.

Objective response rate for E7386 in patients who had not received prior lenvatinib treatment
57.1 %

The objective response rate was 57.1% among patients who had not received prior lenvatinib treatment.

The low–high ranges are Komori's estimate, not figures the company gave.

Everything else in the deck

New initiatives

what they said they're starting
  • Select drug discovery targets with high market potential and accelerate Lead generation through concentrated investment in priority programs.
  • Pursue business development activities with pharmaceutical companies in parallel with Lead generation and seek early licensing opportunities.
  • The website was completely revamped in August 2026.

What decks usually leave out

COMPUTED = worked out by Komori from reported numbers; the rest are stated in this deck

Margins and overheads

where each ¥100 of sales goes
Computed
a year ago-114.3%now-216.0%

Overheads (selling and admin costs): ¥1.3bn

Financial targets

the last five years against the target (green band), where one is stated
Computed
Equity ratio87.6%
how much of the balance sheet is owned outright
+10.3 pts on last year
75%83%90%FY24/9FY25/9FY24/9: 77.3%FY25/9: 87.6%87.6%
Equity ratio
Period%
FY24/977.3
FY25/987.6

Yearly figures are computed by Komori from J-Quants results data (ROE = net profit ÷ average equity). The last point is this year's forecast or latest figure. Targets show only when this deck states them.

Not mentioned in this deck

16
By businessWhat movedCapital spendingShare buybackDividendSelf-rating against planForecast assumptionsRisks priced into the forecastMid-term plan targetsA stated financial targetOrders and backlogPrice and volumeStore or site countHeadcountMarket size and shareInvestor Q&A
Presentation Materials for the Fiscal Year Ended September 2026 | PRISM BioLab Co.,LTD (206A) timely disclosure | Komori